Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 16;29(2):412–421. doi: 10.1038/s41591-022-02190-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 7 — A) Principal component analyses of WT (n = 12, black triangles), R403Q-129SvEv/S4 (n = 6, red circles) and treated (2 doses of AAV9-ABE8e) R403Q-129SvEv/S4 (n = 3, blue squares) mice. Principal component 1 (PC1) provided the best discrimination of phenotype and treatment, accounting for 25% of the variance. PC3 accounted for 12% of the variance. B) and C) Expression levels of genes involved in development of LV hypertrophy, sarcomere structure, cytoskeletal function, calcium handling, extracellular matrix and metabolism were assessed in untreated (n = 6) and treated (two doses of AAV9-ABE8e; n = 3) R403Q-129SvEv/S4 mice. * denotes RNAs with significantly (p < 0.05) altered expression in treated compared to untreated R403Q-129SvEv/S4. Data are presented as mean values ±SD and significance assessed by two-sided T-test (provided in Supplementary Table S3).

Source data